Boston Scientific (NYSE:BSX) Issues Earnings Results

Boston Scientific (NYSE:BSX) announced its earnings results on Wednesday. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03, FiscalAI reports. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same period in the previous year, the business earned $0.75 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific updated its Q3 2026 guidance to 0.800-0.820 EPS and its FY 2026 guidance to 3.280-3.320 EPS.

Here are the key takeaways from Boston Scientific’s conference call:

• Second-quarter results exceeded guidance, with organic revenue growth of 7% and adjusted EPS of $0.86, up 15% year over year and above the $0.82–$0.84 forecast range.
• Boston Scientific reduced its 2026 outlook to 5%–6% organic revenue growth and adjusted EPS of $3.28–$3.32, citing sharper-than-expected pressure in U.S. electrophysiology and a slowdown in WATCHMAN adoption.
• WATCHMAN growth is expected to decline mid- to high-single digits globally in the second half, while EP growth is expected to be flat; management also anticipates limited EPS growth and margin pressure in 2027.
• A company-wide restructuring program is expected to generate approximately $500 million in annualized savings by the end of 2029, with more than half realized by the end of 2027 and reinvestment directed toward priority growth areas.
• Management highlighted strong momentum in interventional cardiology, neuromodulation, interventional oncology, and vascular therapies, alongside longer-term catalysts including Penumbra, coronary IVL, FARAWAVE Ultra, ICE imaging, and potential MiRus TAVR assets.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded down $1.00 on Thursday, hitting $45.04. 2,594,124 shares of the company traded hands, compared to its average volume of 18,205,830. Boston Scientific has a 52 week low of $42.20 and a 52 week high of $109.50. The business has a 50-day simple moving average of $46.57 and a 200 day simple moving average of $62.73. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The stock has a market capitalization of $66.94 billion, a P/E ratio of 18.85, a price-to-earnings-growth ratio of 0.88 and a beta of 0.58.

Boston Scientific announced that its Board of Directors has initiated a share repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at Boston Scientific

In related news, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 9,800 shares of company stock valued at $554,012. Corporate insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific during the fourth quarter valued at $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the 4th quarter valued at about $26,000. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter worth about $26,000. Sfam LLC bought a new stake in Boston Scientific during the fourth quarter worth approximately $29,000. Finally, Pin Oak Investment Advisors Inc. purchased a new stake in Boston Scientific during the third quarter valued at approximately $41,000. 89.07% of the stock is currently owned by institutional investors.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter revenue of $5.442 billion, up 7.5% year over year, while adjusted EPS of $0.86 exceeded the $0.83 consensus estimate. Cardiovascular sales grew 8.3%, and growth was especially strong in APAC and LACA. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: The company raised its expected full-year reported sales-growth range to approximately 5.5%–6.5%, reflecting continued broad-based demand across its medical-device portfolio. It also completed a $2 billion accelerated share repurchase and announced a $1.5 billion investment in MiRus, including an option to acquire its TAVR business. Boston Scientific Q2 revenue rises to $5.442 billion
• Neutral Sentiment: Management launched a multiyear global restructuring program expected to cost $700 million–$800 million through 2029, targeting about $500 million in annual savings. The plan may improve margins over time but introduces near-term costs and potential headcount reductions. Boston Scientific expects headcount reductions amid restructuring initiative
• Negative Sentiment: Boston Scientific lowered its full-year adjusted EPS guidance to $3.28–$3.32 from $3.34–$3.41, below the roughly $3.36 consensus. Third-quarter EPS and revenue guidance also trails analyst expectations. The company cited softer Watchman demand, competition and challenges in electrophysiology. Boston Scientific trims annual profit forecast on softer Watchman device demand
• Negative Sentiment: Analysts responded by cutting valuation targets while retaining favorable ratings: UBS reduced its target to $74 from $95, BTIG lowered its target to $60 from $65, and another fair-value estimate fell to $72.25 from $75. These cuts signal reduced near-term expectations despite continued confidence in BSX’s broader portfolio. Boston Scientific fair value cut as Watchman concerns reset expectations

Analyst Ratings Changes

Several research analysts have issued reports on the company. Evercore set a $65.00 target price on Boston Scientific in a research report on Monday, July 6th. Bank of America cut their target price on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Barclays decreased their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. Leerink Partners set a $60.00 price objective on Boston Scientific in a research note on Thursday. Finally, Robert W. Baird set a $56.00 target price on Boston Scientific in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.28.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.